Enhancement of Liver Targetability through Statistical Optimization and Surface Modification of Biodegradable Nanocapsules Loaded with Lamivudine

Table 4

Results showing various pharmacokinetic parameters after noncompartmental analysis of plasma and liver data obtained from in vivo biodistribution studies of LMV-ACNs.

S. no.	Pharmacokinetic parameter	Plasma			Liver
		LMV Solution	LMV-PLGA ACNs	Surface-modified LMV-PLGA ACNs	LMV Solution	LMV-PLGA ACNs	Surface-modified LMV-PLGA ACNs
1	t1/2 (h)	4.23 ± 0.48	8.13 ± 0.89	11.14 ± 1.24	6.58 ± 1.37	11.56 ± 0.77	15.68 ± 0.90
2	AUC (μg/mL  h)	24.34 ± 4.34	27.78 ± 4.94	30.23 ± 5.76	13.78 ± 3.48	32.94 ± 5.12	54.91 ± 6.68
3	MRT (h)	6.53 ± 0.95	11.64 ± 1.29	16.21 ± 2.20	9.53 ± 1.82	16.52 ± 1.19	22.25 ± 1.52
4	Vss (L/kg)	0.32 ± 0.06	0.28 ± 0.05	0.26 ± 0.05	0.58 ± 0.15	0.23 ± 0.04	0.14 ± 0.02
5	ClT (L/kg/h)	2.05 ± 0.07	3.21 ± 0.22	4.10 ± 0.23	5.32 ± 0.34	3.85 ± 0.32	3.09 ± 0.17

t _1/2: elimination half-life; AUC: area under the time-plasma drug concentration curve; MRT: mean residence time; V_ss: steady state volume of distribution; Cl_T: total body clearance. (The data presented were the mean of three observations, and comparison was made at a significance limit of )